Cargando…
Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation
Clear cell renal cell carcinoma (ccRCC) represents the most common subtype of renal cell carcinoma (RCC). In spite of recent advances in the treatment armamentarium and outcomes with the combined use of immune checkpoint and angiogenesis inhibitors, prediction of responses and selection of patients...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Codon Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497900/ https://www.ncbi.nlm.nih.gov/pubmed/32983840 http://dx.doi.org/10.15586/jkcvhl.2020.135 |
_version_ | 1783583402932305920 |
---|---|
author | Vlachostergios, Panagiotis J. |
author_facet | Vlachostergios, Panagiotis J. |
author_sort | Vlachostergios, Panagiotis J. |
collection | PubMed |
description | Clear cell renal cell carcinoma (ccRCC) represents the most common subtype of renal cell carcinoma (RCC). In spite of recent advances in the treatment armamentarium and outcomes with the combined use of immune checkpoint and angiogenesis inhibitors, prediction of responses and selection of patients remain a challenge. This is a case of ccRCC with recurrence to the liver 1 year following right radical nephrectomy, who rapidly progressed on frontline therapy with axitinib/pembrolizumab. The clinical course and targeted tumor sequencing findings are discussed. In addition to established clinical prognostication in RCC, several surrogate markers of efficacy or/and resistance have been proposed for immunotherapy or/and anti-angiogenic therapy. Since the majority of patients will still progress after these combinations, it is becoming increasingly important to develop robust predictive biomarkers to guide patient selection and sequencing of targeted therapies. |
format | Online Article Text |
id | pubmed-7497900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Codon Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-74979002020-09-25 Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation Vlachostergios, Panagiotis J. J Kidney Cancer VHL Case Report Clear cell renal cell carcinoma (ccRCC) represents the most common subtype of renal cell carcinoma (RCC). In spite of recent advances in the treatment armamentarium and outcomes with the combined use of immune checkpoint and angiogenesis inhibitors, prediction of responses and selection of patients remain a challenge. This is a case of ccRCC with recurrence to the liver 1 year following right radical nephrectomy, who rapidly progressed on frontline therapy with axitinib/pembrolizumab. The clinical course and targeted tumor sequencing findings are discussed. In addition to established clinical prognostication in RCC, several surrogate markers of efficacy or/and resistance have been proposed for immunotherapy or/and anti-angiogenic therapy. Since the majority of patients will still progress after these combinations, it is becoming increasingly important to develop robust predictive biomarkers to guide patient selection and sequencing of targeted therapies. Codon Publications 2020-06-02 /pmc/articles/PMC7497900/ /pubmed/32983840 http://dx.doi.org/10.15586/jkcvhl.2020.135 Text en Copyright: Panagiotis J. Vlachostergios http://creativecommons.org/licenses/by/4.0/ License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Case Report Vlachostergios, Panagiotis J. Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation |
title | Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation |
title_full | Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation |
title_fullStr | Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation |
title_full_unstemmed | Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation |
title_short | Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation |
title_sort | resistance to pembrolizumab and axitinib in renal cell carcinoma: clinical and genomic evaluation |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497900/ https://www.ncbi.nlm.nih.gov/pubmed/32983840 http://dx.doi.org/10.15586/jkcvhl.2020.135 |
work_keys_str_mv | AT vlachostergiospanagiotisj resistancetopembrolizumabandaxitinibinrenalcellcarcinomaclinicalandgenomicevaluation |